Product Name:Baclofen Tablets 20 mg
Description:Baclofen tablets are a type of muscle relaxant used for the relief of muscle spasms, stiffness, and pain associated with muscle spasms and stiffness caused by prescription products, such as prescription medication. This product is a muscle relaxant and antispastic agent.
Indication:Baclofen tablets are indicated for the relief of muscle spasms, stiffness, and pain caused by muscle spasm, and pain caused by prescription medication. The product contains baclofen, a muscle relaxant and anti-inflammatory drug.
Contraindications:Concomitant use with————————————
Dosage Formulations:Tablet
Active Ingredient:Baclofen
Route of administration:Oral
Delivery Time:Overnight shipping
Imported From:
Packaging:10 Tablets in a strip of 10
Packaging Size:1 strip x 10 strip
The active substance in the product is baclofen.
ProductBaclofen tablets are a type of muscle relaxant used for the relief of muscle spasm, stiffness, and pain associated with muscle spasm caused by prescription products such as prescription medication. This product is a muscle relaxant and antispasmodic. Baclofen tablets contain baclofen, a muscle relaxant and a substance that induces the release of an active substance that acts as a depressant, which reduces the activity of the brain. This product contains Baclofen.
Concomitant use with baclofen tablets.
US to UK and Canada for delivery
UK to UK and Canada for delivery
Baclofen tablets are a type of muscle relaxant used for the relief of muscle spasm, stiffness, and pain associated with muscle spasm caused by prescription medication. This product is a muscle relaxant and a substance that induces the release of an active substance that acts as a depressant, which reduces the activity of the brain. Baclofen tablets contain Baclofen.
Baclofen, a nonsteroidal anti-inflammatory drug (NSAID), is classified as a gamma-aminobutyric acid (GABA) receptor agonist. In the United States, this drug is approved by the Food and Drug Administration (FDA) for the treatment of spasticity of the cerebral and spinal cord, spasticity associated with cerebral palsy, and as a muscle relaxant for skeletal muscle. The FDA approved baclofen for the treatment of spasticity associated with cerebral palsy and spasm associated with spasticity in 2009. The drug was first approved by the FDA in the United States by the Food and Drug Administration (FDA) in 1995. Baclofen is a nonselective, competitive GABA A receptor agonist that selectively inhibits GABAB receptors, resulting in increased spasticity.
Spasticity is a common, non-specific, and progressive neurological disorder in which spasticity is a result of the abnormal development of multiple motor neurons, which can be surgically removed by surgery. Despite the fact that baclofen is a safe and effective treatment for spasticity, the long-term benefits of baclofen remain unknown.
Baclofen has been used off-label in the treatment of spasticity of cerebral and spinal cord origin, and it is approved for use in patients who meet the criteria for the following disorders:
Baclofen is a competitive and nonselective agonist of the GABAB receptor, which is found in most patients with muscle spasticity. The mechanism of action of baclofen is that it inhibits the action of the GABAB receptor, resulting in the relaxation of the spastic muscles.
Baclofen has several indications, which have been reported to be effective in treating spasticity associated with spasticity. One indication of baclofen use in this context is spasticity associated with cerebral palsy. Spasticity associated with cerebral palsy is caused by multiple mechanisms, including:
Baclofen has been approved for the treatment of spasticity associated with spasticity in children and adolescents. It can be used in adults for treating spasticity, but it is generally considered to be safe and effective for use in children. It can also be used for cerebral palsy, although it has a limited safety profile.
The effectiveness of baclofen for treating spasticity associated with spasticity in children has been assessed in several studies. However, it was not considered to be effective for treating spasticity associated with cerebral palsy in children because the clinical evidence for this use is limited.
The clinical evidence for baclofen use in children and adolescents with spasticity associated with spastic parapatheremia (SPMP) is limited. In one study, a high-dose intravenous baclofen (10 mg/kg/day) was given to 9 children with SPMP and 3 children with spastic parapatheremia. There was no significant difference between the two groups in the efficacy of baclofen.
Therefore, baclofen may not be suitable for treating spasticity associated with spastic parapatheremia in children.
In addition, baclofen is not approved for use in children. Therefore, it is not recommended for use in children.
The safety and efficacy of baclofen in children have been evaluated in several studies.
The prevalence of baclofen use in children and adolescents is estimated to be approximately 1.7% of the general population. However, it is estimated that approximately 20% of children and adolescents will be treated for baclofen in the future. This study aimed to investigate the prevalence of baclofen use in children and adolescents with and without ADHD.
This study was a descriptive cross-sectional study conducted between March 2024 and January 2024 in the Pediatric and Adolescents Department at Farma University Hospital (Farma University), Faculty of Medicine (Farma University), Ministry of Health and Social Services, Poland. The study sample consisted of 816 children and adolescents from 3 primary academic and medical centers (CAD, MSH, and PMH) aged 12-18 years, with mean age of 9 years. The patients were divided into three groups according to their age (mean age of 9 years, 13-18 years and 11-12 years, respectively) and their gender. The diagnosis was made using DSM-IV-TR criteria, and the data were analyzed using the Statistical Package for the Social Sciences (SPSS) version 21 (IBM Corp., Armonk, NY, USA). Data were expressed as mean ± standard deviation (SD) or frequency. The level of significance was set at P < 0.05. This was followed by a simple one-way ANOVA analysis using SPSS version 21 and a one-way analysis of variance (ANOVA) using SPSS version 22.
The data were collected with a purposive sampling approach, from March 2024 to January 2024 in the pediatric and adolescent medical centers (CAD) at Farma University (Farma University), Faculty of Medicine (Farma University), Ministry of Health and Social Services, Poland. The patients were divided into 3 groups (1-3) according to the age and gender of the patients (female, male and female).
The diagnosis of ADHD was made using DSM-IV-TR criteria and the data were analyzed using the Statistical Package for the Social Sciences (SPSS) version 21 (IBM Corp., Armonk, NY, USA).
This was a descriptive cross-sectional study. The study was approved by the Ethics Committee of Farma University and the Faculty of Medicine (No. FAM-20-2631). The study was conducted in accordance with the Declaration of Helsinki and the study protocol was signed by the Committee on Human Research (CHR).
The study population was composed of patients aged 12-18 years who were admitted to the pediatric and adolescent medical centers (CAD) for baclofen treatment and who had an active baclofen treatment (adrenal function disorder or baclofen). Patients with ADHD, who were treated for ADHD with or without comorbid comorbidities, were excluded. Finally, the sample size was calculated to be 83 patients. The prevalence of baclofen use in children and adolescents aged 12-18 years was estimated to be approximately 1.7% of the general population [].
The study was conducted in compliance with the guidelines for the use of pharmaceutical research ethics committees and adhered to the principles of the Declaration of Helsinki. The study was approved by the ethics committee of Farma University, Poland. Informed consent was obtained from all patients. The study received approval from the ethics committee of Farma University. The research was conducted in accordance with the recommendations of the Declaration of Helsinki and the study protocol was signed by the Committee on Human Research (CHR).
Patients with ADHD and patients with baclofen treatment were excluded from the study. In the analysis of ADHD, patients who were treated with baclofen and who were treated with other treatment (adrenal function disorder or baclofen) were also excluded. The exclusion criteria included: patients with a history of comorbid mental health disorders, such as anxiety or depression, and patients who had a diagnosis of psychosis or schizophrenia.
Statistical analysis was performed using SPSS version 21. The data were presented as mean ± standard deviation (SD) or median (25th and 75th percentile) and the analysis of variance was calculated using the paired or unpaired Student’s t-test. The level of statistical significance was set at P < 0.05.
The study was registered at the European Clinical Research Center under title SC-248537 (24th July 2024).
INDIANAPOLIS,Oct. 30, 2022,Sept. 3, 2022/PRNewswire/ --Ludwig Pharmaceuticals, Inc. (Nasdaq: LUNSW) today announced that it has reached a licensing agreement withto manufacture and market the Baclofen Extended Release™ (branded as Flex-Ora™) pump for oral use in.
is a U. S. licensed generic drugmaker committed to the development, manufacture, and marketing of pharmaceutical products to meet the evolving medical needs of the people and conditions represented in the United States by the U. Food and Drug Administration (FDA). As a generically significant pharmaceutical company,Ludwig is committed to developing innovative, effective medications that meet the evolving needs of the diverse medical communities, including those across the country, in order to deliver better health outcomes for consumers and patients. The company is also expanding its brand product portfolio with a new product line which includes the company'sas well as the company'sproduct. The company'soffering of the company'sproduct,, will include the company'spatent and proprietary products which will provide the company with a generic alternative to the brand product.Ludwig is excited about the positive impact the company has had on its reputation in the pharmaceutical industry. With over 15 years of experience, the company has worked with healthcare professionals and patients to develop a product that meets the highest quality standards, while offering a product that meets the best possible outcomes. In addition, the company has a strong reputation for producing high-quality, FDA-approved generic pharmaceuticals.Ludwig continues to be a trusted and trusted name in the industry, following the company's successful product launch in 2020 inLudwig is well placed to support the advancement of healthcare, and is committed to providing the best possible care to individuals and families.
With the company's commitment to expanding its product portfolio and expanding its brand product line, and the dedication ofandto the highest quality and safest alternatives to generic drugs, the company believes it can provide the highest quality,effective, and safest medicines to consumers, and to the healthcare system worldwide. With the ability to create better choices for patients and healthcare providers,and its broad range of products,the company's commitment to innovation and quality continues to be a top priority. The company is committed to providing the best possible care to patients in every community, and its products are designed to help improve quality of life, and to make the most of life.
About LUDWAGWITLE Pharmaceuticals, Inc. (NYSE: LUNSW) (OTC: LUNSW, ), a privately-held, global, biopharmaceutical company focused on the discovery, development, manufacture and marketing of pharmaceutical products,is a leader in pharmaceutical innovation and consumer healthcare. As a healthcare company, LUDWAGWITLE focuses on discovering, developing and commercializing medicines, and is one of the world's leading biopharmaceutical companies. LUDWAGWITLE has a long history of providing high-quality, FDA-approved medicines, with over 1,000 product recalls as of 2017. The company's mission is to make healthcare better, and to bring affordable medicines to people all around the world. The Company's patents have expired and LUDWAGWITLE is no longer an industry leader in its business.
As a leader in pharmaceutical innovation and consumer healthcare, LUDWAGWITLE provides high-quality, FDA-approved medicines to the communities around the world. For more information, visit.
For additional information about LUDWAGWITLE, visit.
CONTACT:
SOURCE
Stade de France Pharmacy